tradmap

BBLG Earnings Bone Biologics Corp

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$34 -$17 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $535M $1B 2018 2018 2019 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$9M -$4M $0 2018 2018 2019 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$55 -$28 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$2M -$959855 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-53% -27% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–20 of 20
Q2 20262026-06-30-0.862026-08-1410-Q
Q1 20262026-03-31-0.432026-05-1410-Q
FY 20252025-12-31-2.652026-03-0210-K
Q3 20252025-09-30-2.512025-11-1410-Q
Q2 20262025-06-30-3.232026-08-1410-Q
Q1 20262025-03-31-1.922026-05-1410-Q
FY 20252024-12-31-28.962026-03-0210-K
Q3 20252024-09-30-29.092025-11-1410-Q
Q2 20252024-06-30-10.822025-08-1410-Q
Q1 20252024-03-31-1.312025-05-1210-Q
FY 20242023-12-31-34.012025-02-2610-K
Q3 20242023-09-30-37.402024-11-1410-Q
Q2 20242023-06-30-18.572024-08-0910-Q
Q1 20242023-03-31-55.202024-05-1410-Q
FY 20232022-12-31-31.152024-02-2110-K
Q3 20232022-09-30-6.892023-11-1410-Q
Q2 20232022-06-30-3.362023-08-1410-Q
Q2 20182018-06-30-0.622018-08-1410-Q
Q2 20182017-06-30-0.492018-08-1410-Q
Q2 20172016-06-30-0.322017-08-0810-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.